Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.32 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.32 |
| ▸ | CA5A | P35218 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL83632 | 0.89 | — | — | |
| SCHEMBL17685628 | 0.73 | CRBN (0.39) | CRBN | |
| Sulfuric Acid SCHEMBL31648906 | 0.71 | BLM (0.42) | BLMKDM4ECYP2D6CYP2C19NPSR1 | |
| Sulfuric Acid SCHEMBL2891 | 0.71 | BLM (0.42) | BLMKDM4ECYP2D6CYP2C19NPSR1 | |
| Sulfuric Acid SCHEMBL27702892 | 0.71 | BLM (0.42) | BLMKDM4ECYP2D6CYP2C19NPSR1 | |
| Hydrazinecarboxamide SCHEMBL7615707 | 0.67 | TSHR (0.71) | BLMKDM4ECYP2D6CYP2C19NPSR1 | |
| Hydroxyurea SCHEMBL26111871 | 0.67 | CA2 (0.71) | BLMKDM4ECYP2D6CYP2C19NPSR1 | |
| Hydrazinecarboxamide SCHEMBL825388 | 0.67 | TSHR (0.71) | BLMKDM4ECYP2D6CYP2C19NPSR1 | |
| Sulfuric Acid SCHEMBL6829531 | 0.67 | CRBN (0.47) | BLMKDM4ECYP2D6CYP2C19NPSR1 | |
| SCHEMBL3057940 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0031109-B1 | GUANIDINIUM COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MICROBICIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-05-11 | — | — | EP | claimed |
| CN-117567338-A | Novel heteroaryl triazole compounds as pesticides | 拜耳公司 | 2024-02-20 | — | — | CN | disclosed |
| US-9181281-B2 | Prodrugs of neuraminidase inhibitors | SineVir Therapeutics LLC (US) | 2015-11-10 | — | — | US | disclosed |
| EP-2001849-B1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2014-11-26 | — | — | EP | disclosed |
| EP-2276479-B1 | PRODRUGS OF NEURAMINIDASE INHIBITORS | SineVir Therapeutics LLC (US) | 2014-07-02 | — | — | EP | disclosed |
| US-20140155350-A1 | Prodrugs of Neuraminidase Inhibitors | SineVir Therapeutics LLC (US) | 2014-06-05 | — | — | US | disclosed |
| US-8227638-B2 | Process for preparing creatine, creatine monohydrate or guanidinoacetic acid | ALZCHEM TROSTBERG GMBH (DE) | 2012-07-24 | — | — | US | disclosed |
| EP-2468727-A1 | Pyridine and pyrimidine derivatives as MGLUR2 antagonists | F. Hoffmann-La Roche AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-8183262-B2 | Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine | HOFFMANN-LA ROCHE INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20120058937-A9 | Prodrugs of Neuraminidase Inhibitors | TSRL, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| EP-0284254-A2 | Improved polyurea reaction injection molding process | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-09-28 | — | — | EP | disclosed |
| EP-0209983-A1 | Dialkylaminotetrahydroquinazoline | ELI LILLY AND COMPANY (US) | 1987-01-28 | — | — | EP | disclosed |
| US-4622398-A | INCREASING CONCENTRATION OF DOPAMINE AND NOREPINEPHRINE IN BRAIN, ANTAGONIST | ELI LILLY AND COMPANY (US) | 1986-11-11 | — | — | US | disclosed |
| US-4339459-A | FUNGICIDES, BACTERICIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-07-13 | — | — | US | disclosed |
| US-4216161-A | 3,4-Diaminophenyl sulfonic acid esters | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-08-05 | — | — | US | disclosed |
| US-4010272-A | ANTHELMINTICALLY ACTIVE BASICALLY SUBSTITUTED 2-CARBALKOXY-AMINO-BENZIMIDAZOLYL-5(6)-PHENYL ETHERS AND -KETONES | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-03-01 | — | — | US | disclosed |
| US-3996369-A | Anthelmintically active 2-carbalkoxyamino benzimidazolyl-5(6)-sulfonic acid phenyl esters | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-12-07 | — | — | US | disclosed |
| US-3996368-A | Anthelmintically active 2-carbalkoxyamino-5(6)-phenyl sulfonyloxy benzimidazoles | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-12-07 | — | — | US | disclosed |
| US-3984561-A | Anthelmintically active 2-carbalkoxy-amino-benzimidazole-5(6)-phenyl ethers and method for using the same | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-10-05 | — | — | US | disclosed |
| US-3954791-A | Anthelmintically active 2-carbalkoxy-amino-benzimidazole-5(6)-phenyl ethers | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058937-A9 | Prodrugs of Neuraminidase Inhibitors | NEU1, ANPEP, NEU4 | MAOA 397/4885MAOB 265/4885BLM 4874/4885 |
| US-20140155350-A1 | Prodrugs of Neuraminidase Inhibitors | NEU1, ANPEP, NEU4 | MAOA 397/4885MAOB 265/4885BLM 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.